Researchers conducted a randomized, placebo-controlled phase 3 trial involving 418 adults with moderately to severely active ulcerative colitis. These participants had tried other treatments like corticosteroids, azathioprine, biologics, JAK inhibitors, or S1P inhibitors without success or had become dependent on steroids. The study took place across 153 sites in 25 countries.
The participants were randomly assigned to receive either subcutaneous guselkumab injections or a matched placebo. The drug was given at weeks 0, 4, and 8, followed by maintenance doses every 8 weeks or every 4 weeks depending on the group. The main goal was to see if patients achieved clinical remission by week 12.
Results showed that a significantly greater proportion of patients in the guselkumab groups achieved remission compared to the placebo group. By week 24, about 35% to 36% of those on the drug were in remission, compared to only 9% on placebo. No new safety concerns were identified, and there were no treatment-related deaths.
While the findings are positive, this is an ongoing trial. Readers should understand that this establishes a potential treatment option but does not yet prove long-term safety or effectiveness in all patients. More data is needed before this becomes a standard recommendation.